Biogen (BIIB) · Biotechnology
Biogen Q2 2026 earnings: summary, key numbers & outlook
Results filed 29 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Biogen's Growth Portfolio now outsells its legacy MS franchise after the Apellis acquisition, as management pivots toward a run of late-stage pipeline readouts beginning with lupus data by year-end.
Biogen's mix shifted toward newer products. Growth Portfolio revenue of $1.06 billion exceeded the legacy MS portfolio. The Apellis acquisition closed on May 14, 2026, adding SYFOVRE and EMPAVELI. SPINRAZA's high-dose regimen is converting faster than expected, SKYCLARYS is expanding in Europe, and ZURZUVAE launched in Germany. The FDA approved LEQEMBI IQLIK, an at-home initiation dose.
Management is steering toward a multi-year registrational cycle, with five late-stage readouts expected over the next four quarters, starting with litifilimab in lupus (SLE) by the end of 2026. It is also adding early-stage programs through the pending RayThera deal. The main tension is that the pipeline must deliver as the legacy MS business declines and Apellis financing weighs on earnings.
No call transcript for this quarter, so this summary also draws on: The Motley Fool (via Webull) ↗.
Key numbers
- Total revenue · GAAP
- $2.7B
- Net income attributable to Biogen · GAAP
- $97.5M
- Diluted EPS · GAAP
- $0.66
- Non-GAAP diluted EPS · non-GAAP
- $3.60
- Net cash flow from operations · GAAP
- $448.9M
- Free cash flow · non-GAAP
- $408.0M
up 3% from a year ago
down from $634.8 million a year ago
down 85% from a year ago
down 34% from a year ago
up from $160.9 million a year ago
up from $134.3 million a year ago
| Segment or metric | Value | Change |
|---|---|---|
| SPINRAZA | $402 million | up 2% year-over-year |
| LEQEMBI global in-market sales | $184 million | up 15% year-over-year |
| SKYCLARYS | $168 million | up 29% year-over-year |
| ZURZUVAE | $71 million | up 53% year-over-year |
| SYFOVRE (full quarter) | $162 million | up 8% year-over-year |
| EMPAVELI (full quarter) | $46 million | up 123% year-over-year |
| VUMERITY | $197 million | down 7% year-over-year |
Where each number comes from
- Total revenue: “Total Revenue (in millions) | $2,736 | $2,646 | 3% | 2%”
- Net income attributable to Biogen: “Net income attributable to Biogen Inc. | $97.5 | $634.8 | $417.0 | $875.3”
- Diluted EPS: “GAAP diluted EPS | $0.66 | $4.33 | (85)% | N/A”
- Non-GAAP diluted EPS: “Non-GAAP diluted EPS | $3.60 | $5.47 | (34)% | N/A”
- Net cash flow from operations: “Net cash provided by (used in) operating activities | $448.9 | $160.9 | $1,094.4 | $420.2”
- Free cash flow: “Less: Purchases of property, plant and equipment | 40.9 | 26.6 | 92.1 | 63.7 Free cash flow | $408.0 | $134.3 | $1,002.3 | $356.5”
- SPINRAZA: “SPINRAZA revenue of $402 million, up 2% year-over-year, driven by demand and stocking for the high-dose regimen”
- LEQEMBI global in-market sales: “LEQEMBI global in-market sales of $184 million, up 15% year-over-year, with U.S. in-market sales of $97 million”
- SKYCLARYS: “SKYCLARYS revenue of $168 million, up 29% year-over-year, primarily related to an increase in global demand”
- ZURZUVAE: “ZURZUVAE revenue of $71 million, up 53% year-over-year, driven by demand growth”
- SYFOVRE (full quarter): “SYFOVRE revenue of $162 million for the full second quarter, up 8% year-over-year, showed its strongest quarterly demand since launch”
- EMPAVELI (full quarter): “EMPAVELI revenue of $46 million for the full second quarter, up 123% year-over-year, driven by demand growth”
- VUMERITY: “VUMERITY second quarter revenue of $197 million, down 7% year-over-year, primarily impacted by inventory dynamics”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $2.7B | +3.4% | +10.4% |
| Net income | $97.5M | −84.6% | −69.5% |
| Diluted EPS | $0.66 | −84.8% | −69.3% |
| Free cash flow | $408.0M | +203.8% | −31.3% |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Underlying non-GAAP diluted EPS | full year 2026 | $15.85 to $16.85 |
| Reported non-GAAP diluted EPS | full year 2026 | $12.00 to $13.00 |
| Combined non-GAAP R&D and SG&A expense | second half of 2026 | $2.65 billion and $2.70 billion |
| Apellis dilution to non-GAAP EPS | full year 2026 | approximately $0.85 |
Key takeaways
Growth Portfolio now outsells legacy MS franchise
Growth Portfolio revenue of $1.06 billion grew 24% year-over-year and exceeded the legacy MS portfolio. This marks the shift in Biogen's commercial base toward newer products.
Apellis adds SYFOVRE and EMPAVELI to the portfolio
The acquisition closed May 14, 2026, and SYFOVRE posted its strongest quarterly demand since launch. EMPAVELI grew 123% for the full quarter, and management expects at least $250 million of run rate synergies exiting 2027.
SPINRAZA high-dose conversion is ahead of expectations
Conversion to the high-dose regimen is ahead of company expectations in all launched geographies, supporting SPINRAZA's franchise. The release calls the SPINRAZA HD launch successful.
LEQEMBI IQLIK approval enables at-home initiation
The FDA approved IQLIK as an initiation dose, described as a first-of-its-kind anti-amyloid at-home option. LEQEMBI global in-market sales were $184 million, up 15%, with U.S. sales of $97 million growing sequentially.
Five registrational readouts start with lupus data
Litifilimab in SLE reports by end of 2026, with litifilimab in CLE, felzartamab in AMR and zorevunersen in Dravet syndrome next year. Diranersen showed proof-of-concept in Alzheimer's as the first tau-directed agent to show clinical efficacy, and Biogen plans Phase 3.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $2.5B * |
| Q1 2025 | $2.4B |
| Q2 2025 | $2.6B |
| Q3 2025 | $2.5B |
| Q4 2025 | $2.3B * |
| Q1 2026 | $2.5B |
| Q2 2026 | $2.7B |
| Q3 2026 | $2.8B |
Data
| Q1 2025 | $1.64 |
| Q2 2025 | $4.33 |
| Q3 2025 | $3.17 |
| Q1 2026 | $2.15 |
| Q2 2026 | $0.66 |
| Q3 2026 | -$0.14 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | $721.6M |
| Q1 2025 | $222.2M |
| Q2 2025 | $134.3M |
| Q3 2025 | $1.2B |
| Q4 2025 | $468.0M |
| Q1 2026 | $594.3M |
| Q2 2026 | $408.0M |
| Q3 2026 | $600.4M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What did Biogen launch or get approved this quarter?
The FDA approved LEQEMBI IQLIK as an at-home initiation dose, and the SPINRAZA high-dose regimen launched with conversion ahead of expectations. ZURZUVAE also launched in Germany, its first commercial launch outside the U.S. for postpartum depression.
How is the Apellis acquisition performing?
SYFOVRE had its strongest quarterly demand since launch and EMPAVELI grew 123% for the full quarter. Biogen expects at least $250 million of run rate synergies exiting 2027 and accretion to Non-GAAP EPS in 2027.
Which pipeline readouts are coming next?
Litifilimab in SLE is expected by end of 2026. Litifilimab in CLE, felzartamab in AMR and zorevunersen in Dravet syndrome follow next year.
What is happening with Biogen's multiple sclerosis business?
MS product revenue fell 13% year-over-year, while the legacy MS portfolio held up on resilient TYSABRI performance. BIIB091 showed Phase 2 proof-of-concept in relapsing-remitting MS, and Biogen is exploring next steps.
What new programs and deals did Biogen add?
Biogen exercised its option on Ionis's BIIB147 for ALS and has a pending RayThera acquisition that adds immunology programs. It also plans a new Phase 2 felzartamab study in Graves' disease.
Documents
SEC filing